Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 50Lymphoid 9Other hematologic neoplasm 7Thoracic 2Gastrointestinal 2Other solid neoplasm 1Myeloid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 60Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × daratumumab × Thoracic × Clear all
NCT03098550 2021-07-23

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
105 enrolled 21 charts
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT03023423 2019-11-20

DARZALEX

Janssen Research & Development, LLC

Phase 1/2 Completed
100 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡